Cord blood transplant for Epstein-Barr virus diseases
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 80 years old.
- You must have a diagnosed EBV-related condition (chronic active EBV infection, EBV-related hemophagocytic syndrome, or EBV-related lymphoma).
- For lymphoma: you must have already tried standard treatment that didn't work or stopped working.
- You must be well enough to get out of bed (ECOG 0-2 or Lansky 60+ for children).
- You cannot have another cancer, uncontrolled infection, severe heart disease, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
Hear when a new Epstein-Barr Virus-associated Lymphoproliferative Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.